Safi Shahda
Hematology & Oncology · Indianapolis, INNPI 1265691935
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,800 of the $13,830 with a category attached, or 99.8%. Eli Lilly accounts for 99.8% of it on its own, with 1 other manufacturer making up the rest.
Across 2 payments — averaging $6915.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$14K
- Exelixis Inc.$30
Across 24 payments — averaging $49,878 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1M
- Merck$100K
- Incyte Corporation$33K
- Array Biopharma Inc$21K
- AstraZeneca$5K
What the payments were for
- Consulting fees$13,800100%
- Food & beverage$300%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 1 | $13,800 |
| Exelixis Inc. | 1 | $30 |
How this compares
$13,830 in reported general payments places this provider in the 70th percentile of 224 hematology & oncology providers in Indiana.
Other hematology & oncology in Indianapolis
- Richard GaynorIndianapolis$3.7M
- Ruemu BirhirayIndianapolis$3.1M
- Anand TandraIndianapolis$280K
- Attaya SuvannasankhaIndianapolis$253K
- Michael DuganIndianapolis$236K
- Daniel MiltonIndianapolis$231K
- Amro ElshouryIndianapolis$212K
- Brian MulherinIndianapolis$175K
- Muhammad Sarfraz NawazIndianapolis$172K
- John EdwardsIndianapolis$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.